Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (2016 - 2025)

Plus Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $138.7 million for Q4 2025.

  • Quarterly Shares Outstanding rose 2153.15% to $138.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138.7 million through Dec 2025, up 2153.15% year-over-year, with the annual reading at $138.7 million for FY2025, 2153.15% up from the prior year.
  • Shares Outstanding was $138.9 million for Q4 2025 at Plus Therapeutics, up from $131.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $138.9 million in Q4 2025 and troughed at $1.0 in Q1 2023.
  • The 5-year median for Shares Outstanding is $1.9 million (2022), against an average of $17.1 million.
  • Year-over-year, Shares Outstanding crashed 99.98% in 2022 and then soared 315205.23% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $1.0 million in 2021, then skyrocketed by 116.64% to $2.2 million in 2022, then soared by 101.9% to $4.5 million in 2023, then surged by 36.09% to $6.2 million in 2024, then surged by 2153.15% to $138.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Outstanding are $138.7 million (Q4 2025), $131.9 million (Q3 2025), and $1952.0 (Q2 2025).